Submit Your Feeds

Business News • PR NewsWire • Pharmacyclics Announces Presentation of Results From Phase I Trial of Its First-in-Human Btk Inhibitor: PCI-32765

Pharmacyclics Announces Presentation of Results From Phase I Trial of Its First-in-Human Btk Inhibitor: PCI-32765
Pharmacyclics Announces Presentation of Results From Phase I Trial of Its First-in-Human Btk Inhibitor: PCI-32765

CHICAGO and SUNNYVALE, Calif., June 5 /PRNewswire-FirstCall/ -- Pharmacyclics, Inc. (Nasdaq: PCYC) today announced results from a Phase I study of its novel orally administered Bruton's tyrosine kinase (Btk) inhibitor, PCI-32765, in patients with relapsed or refractory B cell non-Hodgkin's lymphoma

View More : http://www.prnewswire.com/news-releases/pharmacyclics-announces-presentation-of-results-from-phase-i-trial-of-its-first-...
Releted News by prnewswire
Delcath Highlights Phase III Trial Results Presented at ASCO
Pharmacyclics Announces Presentation of Results From Phase I Trial of Its First-in-Human Btk Inhibitor: PCI-32765
Study at ASCO Shows Novartis Drug Afinitor® First to Shrink SEGA Brain Tumors in Children and Adults With Tuberous Sclerosis
U.S. Census Bureau Daily Feature for June 6
Home Sitemap Contact Us
© businessNewsNewsNews.com